NASDAQ:MYOK - Myokardia Stock Price, Forecast & News

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

Myokardia Inc (NASDAQ:MYOK) issued its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($1.34) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.91) by $0.57. View Myokardia's Earnings History.

Myokardia is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Myokardia.

10 Wall Street analysts have issued 12-month price objectives for Myokardia's shares. Their forecasts range from $70.00 to $90.00. On average, they expect Myokardia's share price to reach $80.00 in the next year. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for Myokardia.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myokardia.

News headlines about MYOK stock have trended very negative recently, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myokardia earned a coverage optimism score of -3.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Myokardia.

Myokardia saw a decrease in short interest in the month of October. As of October 15th, there was short interest totalling 4,810,000 shares, a decrease of 6.4% from the September 15th total of 5,140,000 shares. Based on an average daily volume of 278,800 shares, the days-to-cover ratio is currently 17.3 days. Approximately 11.0% of the shares of the stock are sold short. View Myokardia's Current Options Chain.

Some companies that are related to Myokardia include GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Catalent (CTLT) and Perrigo (PRGO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myokardia investors own include Exelixis (EXEL), CVS Health (CVS), Micron Technology (MU), CA (CA), NVIDIA (NVDA), BlackRock (BLK), Johnson & Johnson (JNJ), Kratos Defense & Security Solutions (KTOS), Amgen (AMGN) and Alibaba Group (BABA).

Myokardia's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (2.11%), Orbimed Advisors LLC (1.69%), Pictet Asset Management Ltd. (0.73%), Voya Investment Management LLC (0.52%), Rhenman & Partners Asset Management AB (0.43%) and Castleark Management LLC (0.29%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, June Lee, Kevin P Starr, Marc Semigran, Sanofi and Taylor C Harris. View Institutional Ownership Trends for Myokardia.

MYOK stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Rhenman & Partners Asset Management AB, Voya Investment Management LLC, Pictet Asset Management Ltd., Squarepoint Ops LLC, State Street Corp, grace capital and Partner Investment Management L.P.. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, June Lee, Sanofi and Taylor C Harris. View Insider Buying and Selling for Myokardia.

MYOK stock was bought by a variety of institutional investors in the last quarter, including Castleark Management LLC, California Public Employees Retirement System, State of New Jersey Common Pension Fund D, Man Group plc, First Trust Advisors LP, Handelsbanken Fonder AB, Nisa Investment Advisors LLC and NJ State Employees Deferred Compensation Plan. Company insiders that have bought Myokardia stock in the last two years include Anastasios Gianakakos and Sanofi. View Insider Buying and Selling for Myokardia.

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYOK stock can currently be purchased for approximately $67.43.

Myokardia has a market capitalization of $3.12 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-67,700,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Myokardia employs 165 workers across the globe.View Additional Information About Myokardia.

The official website for Myokardia is http://www.myokardia.com/.

Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]